Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
Neurocrine Biosciences will acquire rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-
April 06, 2026
Trump signs order authorizing pipeline project partially reviving Keystone XL line
Roku raises annual platform revenue forecast, shares climb
Insurer AIG's quarterly profit surges on steep fall in catastrophe losses
Mexico government holds growth forecast despite recent slowdown
Roblox slashes annual bookings forecast as new safety features take their toll
Britney Spears charged with one misdemeanor in DUI case